SPDL1 and COVID-19: Circulating levels of sPD‐L2 together with an altered CD4/CD8 ratio could be used as indicative of the persistence of lung lesions post‐COVID‐19 in COVID‐ILD patients, although sPD‐L1 could be helpful to improve the diagnosis during acute COVID‐19.